Speaker
Description
Antiviral medicine plays a crucial role in treating and preventing influenza by Inhibiting viral replication, reducing symptom severity and limiting complications. Major antivirals used block neuraminidase such as zanamivir or inhibit viral RNA replication as baloxavir. However, none of these drugs are protective against secondary effects such as inflammatory burst well as bacterial superinfections.
We have patented a structural analogue of pyruvate that was effective against human, animal and bird influenza viruses. Its mode of action is based on competitive inhibition of neuraminidase as well as blocking the energy supply in cells infected by the virus. In addition, the compound opposes several secondary effects associated with influenza viruses, such an inflammatory response (cytokine burst), airway inflammation as well as secondary bacterial and fungal infections.
The product is suitable for inhalation in humans and can be administered to animals and birds via nebulization.
| Registration ID | #139 |
|---|---|
| Professional status of the speaker | Senior Scientist |
| Junior scientist status | No, I am not a junior scientist. |
Authors
External references
- 47
